---
title: "HUALAN BIOLOGICAL released its 2024 annual performance, with a net profit attributable to the parent company of 1.088 billion yuan, a year-on-year decrease of 26.57%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233601707.md"
description: "HUALAN BIOLOGICAL released its 2024 annual report, with operating revenue of 4.379 billion yuan, a year-on-year decrease of 18.02%; net profit attributable to shareholders was 1.088 billion yuan, a year-on-year decrease of 26.57%. Earnings per share were 0.5958 yuan, and it plans to distribute a cash dividend of 2 yuan for every 10 shares. The company has built multiple plasma stations and received approval for new plasma stations, with plasma collection reaching a record high of 1,586.37 tons, a year-on-year increase of 18.18%"
datetime: "2025-03-28T09:28:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233601707.md)
  - [en](https://longbridge.com/en/news/233601707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233601707.md)
---

# HUALAN BIOLOGICAL released its 2024 annual performance, with a net profit attributable to the parent company of 1.088 billion yuan, a year-on-year decrease of 26.57%

According to the Zhitong Finance APP, HUALAN BIOLOGICAL (002007.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 4.379 billion yuan, a year-on-year decrease of 18.02%. The net profit attributable to shareholders of the listed company was 1.088 billion yuan, a year-on-year decrease of 26.57%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 981 million yuan, a year-on-year decrease of 22.56%. The basic earnings per share were 0.5958 yuan. The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the company completed the construction of the Dengzhou plasma station, Xiangcheng plasma station, Qixian plasma station, and Wushan plasma station, obtained plasma collection licenses, and began plasma collection; the company was approved to set up a new single plasma collection station in Fengdu County, Chongqing, and the Fengdu plasma station is progressing with construction work as planned, striving for early completion and acceptance. The company places great importance on the quality management of single plasma collection stations, establishing and continuously improving the quality management system for single plasma collection stations. Six plasma stations, including Hezhou plasma station, Bozhai plasma station, Fengqiu plasma station, Huaxian plasma station, Xunxian plasma station, and Lushan plasma station, successfully passed the renewal of the single plasma collection license.

While increasing the opening of new plasma stations, the company is actively promoting plasma collection work through multiple measures, such as strengthening performance assessments and building the management team of plasma stations, stimulating internal vitality, optimizing blood source management plans, and focusing on improving the quality and quantity of new plasma stations. The company's plasma collection volume reached a historical high, totaling 1,586.37 tons in 2024, an increase of 18.18% compared to the previous year

### Related Stocks

- [002007.CN](https://longbridge.com/en/quote/002007.CN.md)

## Related News & Research

- [Poland - Factors to Watch August 3](https://longbridge.com/en/news/294649419.md)
- [Telkom expects FY2027 capex intensity within 12%-15% guidance range](https://longbridge.com/en/news/294648011.md)
- [Samse flags uncertain outlook, sees only gradual market stabilization without confirming durable rebound](https://longbridge.com/en/news/294401817.md)
- [Financiera Independencia releases transcript of 2Q26 earnings call](https://longbridge.com/en/news/294544237.md)
- [Stor-Age agrees to buy 10 Xtraspace self-storage sites for R 387 million](https://longbridge.com/en/news/294653868.md)